| Not Yet Recruiting | Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis NCT07220252 | TG Therapeutics, Inc. | Phase 2 / Phase 3 |
| Recruiting | A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and NCT07161258 | Hoffmann-La Roche | Phase 2 |
| Not Yet Recruiting | A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple Sclerosis (RMS) NCT07138833 | Qilu Pharmaceutical (Hainan) Co., Ltd. | Phase 4 |
| Recruiting | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Mul NCT06846281 | Novartis Pharmaceuticals | Phase 3 |
| Recruiting | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcu NCT07211633 | TG Therapeutics, Inc. | Phase 3 |
| Recruiting | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participant NCT07483450 | Hoffmann-La Roche | Phase 4 |
| Recruiting | Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus NCT06847724 | Sandoz | Phase 3 |
| Recruiting | An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Scle NCT06617793 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) NCT06564311 | Zenas BioPharma (USA), LLC | Phase 2 |
| Recruiting | Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod NCT06529406 | University of Colorado, Denver | Phase 4 |
| Recruiting | A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Rela NCT06433752 | TG Therapeutics, Inc. | — |
| Active Not Recruiting | A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis NCT06396039 | Bristol-Myers Squibb | Phase 4 |
| Withdrawn | A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Scleros NCT06104683 | Loxo Oncology, Inc. | Phase 2 |
| Active Not Recruiting | A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Scleros NCT06372145 | Sanofi | Phase 3 |
| Recruiting | A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk NCT06143514 | TG Therapeutics, Inc. | — |
| Recruiting | Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study NCT05809986 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years NCT05776888 | Novartis Pharmaceuticals | — |
| Recruiting | Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab NCT05877963 | TG Therapeutics, Inc. | Phase 3 |
| Completed | A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple NCT06395909 | Novartis | — |
| Completed | Characterizing the Use of Ofatumumab in a Real World Setting NCT05090033 | Novartis Pharmaceuticals | — |
| Completed | Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD2 NCT06526000 | Novartis | — |
| Withdrawn | A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis NCT05496894 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 2 |
| Completed | Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf NCT05266469 | Novartis Pharmaceuticals | — |
| Completed | Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China NCT05199571 | Novartis Pharmaceuticals | Phase 4 |
| Recruiting | A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis NCT05344469 | Novartis Pharmaceuticals | — |
| Completed | A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pha NCT05232825 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) NCT05119569 | Hoffmann-La Roche | Phase 2 |
| Active Not Recruiting | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosi NCT05147220 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosi NCT05156281 | Novartis Pharmaceuticals | Phase 3 |
| Withdrawn | Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis NCT05077956 | Providence Health & Services | — |
| Withdrawn | Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple NCT04079088 | Biogen | Phase 2 |
| Completed | Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (R NCT04869358 | Novartis Pharmaceuticals | Phase 4 |
| Completed | A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofa NCT04847596 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sc NCT04586023 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple NCT04586010 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | Effects of Ocrevus in Relapsing Multiple Sclerosis NCT04387734 | Georgia State University | Phase 4 |
| Completed | A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Of NCT04667117 | Novartis Pharmaceuticals | Phase 4 |
| Completed | A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Scl NCT04626921 | Clene Nanomedicine | Phase 2 / Phase 3 |
| Completed | A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing M NCT04486716 | Novartis Pharmaceuticals | Phase 3 |
| Completed | 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple S NCT04510220 | Brigham and Women's Hospital | Phase 3 |
| Unknown | Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS) NCT04121065 | Neuromed IRCCS | — |
| Active Not Recruiting | Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset NCT04466150 | University of California, San Francisco | Phase 4 |
| Completed | An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning NCT04353492 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Study of Evobrutinib in Participants With RMS (evolutionRMS 2) NCT04338061 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 3 |
| Completed | Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SA NCT04410978 | Sanofi | Phase 3 |
| Terminated | Study of Evobrutinib in Participants With RMS (evolutionRMS 1) NCT04338022 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 3 |
| Completed | Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SA NCT04410991 | Sanofi | Phase 3 |
| Recruiting | Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) NCT04047628 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) NCT04121403 | Oslo University Hospital | Phase 3 |
| Completed | Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclero NCT03996291 | Sanofi | Phase 2 |
| Completed | Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis NCT03889639 | Sanofi | Phase 2 |
| Completed | To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis NCT03856619 | Sanofi | Phase 4 |
| Completed | Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-t NCT03623243 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS NCT03650114 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed b NCT03249714 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment Wit NCT03257358 | Novartis Pharmaceuticals | Phase 4 |
| Terminated | Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients NCT03183869 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 |
| Completed | Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis NCT02792218 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran NCT04928313 | Cinnagen | — |
| Completed | Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ NCT02254304 | Merck KGaA, Darmstadt, Germany | Phase 4 |
| Terminated | Natalizumab Subcutaneous Immunogenicity and Safety Study NCT02142192 | Biogen | Phase 2 |
| Withdrawn | Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy NCT02234869 | Biogen | Phase 4 |
| Terminated | Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other The NCT02241785 | Biogen | Phase 4 |
| Completed | Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis NCT02047734 | Celgene | Phase 3 |
| Completed | Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Inter NCT01939002 | Biogen | Phase 3 |
| Completed | Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients NCT01628393 | Celgene | Phase 2 / Phase 3 |
| Completed | An Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif® Injections Using the RebiSm NCT01601080 | Merck KGaA, Darmstadt, Germany | — |
| Withdrawn | A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and T NCT01404117 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Completed | Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis ( NCT01601119 | Merck KGaA, Darmstadt, Germany | — |
| Completed | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple S NCT01412333 | Hoffmann-La Roche | Phase 3 |
| Completed | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple S NCT01247324 | Hoffmann-La Roche | Phase 3 |
| Completed | Long-Term Safety and Efficacy Study of Peginterferon Beta-1a NCT01332019 | Biogen | Phase 3 |
| Completed | Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Boos NCT01199861 | Novartis | Phase 3 |
| Terminated | A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease C NCT01047319 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 |
| Completed | Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients NCT01127750 | Novartis | Phase 3 |
| Completed | Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study NCT01006941 | Rigshospitalet, Denmark | Phase 2 |
| Completed | JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab NCT01070836 | Biogen | — |
| Completed | The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial NCT01034579 | EMD Serono | Phase 4 |
| Terminated | A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course NCT00988052 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 |
| Completed | Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis NCT00906399 | Biogen | Phase 3 |
| Terminated | Atacicept in Multiple Sclerosis Extension Study, Phase II NCT00853762 | EMD Serono | Phase 2 |
| Completed | CDP323 Biomarker Study NCT00726648 | UCB Pharma | Phase 1 / Phase 2 |
| Terminated | A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) NCT00642902 | EMD Serono | Phase 2 |
| Completed | Transition to Rebif New Formulation NCT00619307 | Merck KGaA, Darmstadt, Germany | Phase 3 |
| Completed | Rebif New Formulation (RNF) Quality of Life (QOL) Study NCT00472797 | EMD Serono | Phase 3 |